LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF7 | GSK1904529A | 0.37 | uM | LJP6 | 72 | hr | 1209 | 2171 | 4012 | 0.5425 | 0.4041 |
MCF7 | GSK1904529A | 1.11 | uM | LJP6 | 72 | hr | 1209 | 2046 | 4012 | 0.5101 | 0.3549 |
MCF7 | GSK1904529A | 3.33 | uM | LJP6 | 72 | hr | 1209 | 1999 | 4012 | 0.4988 | 0.3374 |
MCF7 | GSK1904529A | 10 | uM | LJP6 | 72 | hr | 1209 | 1997 | 4012 | 0.4988 | 0.3375 |
MCF7 | Linsitinib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 3271 | 4203 | 0.7776 | 0.7377 |
MCF7 | Linsitinib | 0.12 | uM | LJP5 | 72 | hr | 1209 | 2975 | 4203 | 0.7074 | 0.6482 |
MCF7 | Linsitinib | 0.37 | uM | LJP5 | 72 | hr | 1209 | 2335 | 4203 | 0.5554 | 0.4407 |
MCF7 | Linsitinib | 1.11 | uM | LJP5 | 72 | hr | 1209 | 2053 | 4203 | 0.4890 | 0.3419 |
MCF7 | Linsitinib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 1932 | 4203 | 0.4600 | 0.2976 |
MCF7 | Linsitinib | 10 | uM | LJP5 | 72 | hr | 1209 | 1647 | 4203 | 0.3926 | 0.1877 |
MCF7 | Ruxolitinib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4326 | 4203 | 1.0260 | 1.0237 |
MCF7 | Ruxolitinib | 0.12 | uM | LJP5 | 72 | hr | 1209 | 4206 | 4203 | 1.0013 | 1.0020 |
MCF7 | Ruxolitinib | 0.37 | uM | LJP5 | 72 | hr | 1209 | 4219 | 4203 | 1.0039 | 1.0043 |
MCF7 | Ruxolitinib | 1.11 | uM | LJP5 | 72 | hr | 1209 | 4523 | 4203 | 1.0753 | 1.0811 |
MCF7 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 4523 | 4203 | 1.0761 | 1.0827 |
MCF7 | Ruxolitinib | 10 | uM | LJP5 | 72 | hr | 1209 | 3462 | 4203 | 0.8236 | 0.7938 |
MCF7 | Momelotinib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 3799 | 4203 | 0.9044 | 0.8912 |
MCF7 | Momelotinib | 0.12 | uM | LJP5 | 72 | hr | 1209 | 3956 | 4203 | 0.9422 | 0.9353 |
MCF7 | Momelotinib | 0.37 | uM | LJP5 | 72 | hr | 1209 | 3620 | 4203 | 0.8624 | 0.8424 |
MCF7 | Momelotinib | 1.11 | uM | LJP5 | 72 | hr | 1209 | 2752 | 4203 | 0.6544 | 0.5782 |
MCF7 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 1704 | 4203 | 0.4057 | 0.2098 |
MCF7 | Momelotinib | 10 | uM | LJP5 | 72 | hr | 1209 | 1263 | 4203 | 0.3000 | 0.0219 |
MCF7 | Fedratinib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4036 | 4203 | 0.9615 | 0.9563 |
MCF7 | Fedratinib | 0.12 | uM | LJP5 | 72 | hr | 1209 | 3749 | 4203 | 0.8898 | 0.8710 |
MCF7 | Fedratinib | 0.37 | uM | LJP5 | 72 | hr | 1209 | 3198 | 4203 | 0.7612 | 0.7177 |